Alector, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia. The company’s core technology is the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier delivery system designed to transport antibodies, enzymes, and siRNA therapeutics into the central nervous system. Its lead clinical candidate, nivisnebart, is a progranulin-elevating antibody co-developed with GlaxoSmithKline for early Alzheimer’s disease. The preclinical pipeline includes AL137, an anti-amyloid beta antibody; AL050, a GCase enzyme replacement therapy for Parkinson’s disease and Lewy body dementia; and ABC-enabled siRNA programs targeting tau, alpha-synuclein, and NLRP3. Alector also maintains a licensing agreement with Genentech for the GCase enzyme replacement therapy. The company utilizes expertise in protein engineering, antibody discovery, and nucleic acid engineering to address unmet medical needs in neurodegeneration.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage alector.com
Sector Healthcare IR page investors.alector.com
Tags
neurodegenerative diseases, alzheimer's disease, parkinson's disease, lew body dementia, blood-brain barrier delivery, antibody therapeutics, sirna therapeutics, enzyme replacement therapy, protein engineering, clinical-stage, Alector Brain Carrier, ABC, nivisnebart, AL101, GSK4527226, AL137, AL037, AL050, AL064, ADP062-ABC, ADP065-ABC, GlaxoSmithKline, Genentech
Press page —

Metrics

Valuation  
Market cap $ 207.709M
Market cap (USD) $ 207.709M
P/E 5.29
PEG —
P/BV 1.78
P/S 1.20
P/OCF -1.39
P/FCF -1.38
Dividend yield —
Turnover / mcap —
Returns  
ROE -181.6%
ROI -354.3%
ROIC -290.1%
Profit margin -679.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 79.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 21.045M 100.558M 97.062M 133.617M 207.085M 21.098M 21.219M 27.508M
Net profit -142.929M -119.049M -130.391M -133.31M -36.329M -190.228M -105.385M -52.248M
Free cash flow -184.072M -231.16M -186.543M -24.446M 295.304M -171.766M -114.573M 125.58M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 1.56 1.89 7.98 9.23 20.65 15.13 17.23 —
Price performance 12m -0.17 -0.76 -0.14 -0.55 0.36 -0.12 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 238,000 0.00 — — — — — — —
↳ YoY growth -100.0%
Borrowings, current (USD) — — — — — — — — 0.00 366,000
Borrowings, non-current (USD) — — — — — — — 0.00 9.39M 9.32M
Lease liabilities (USD) — — 38.9M 48M 51.3M 47.6M 43.3M 38.9M 33.1M 26.5M
Cash and deposits (USD) 51M 32.5M 65.5M 89.6M 50M 329M 154M 74.6M 33M 65.8M
Right-of-use assets (USD) — — 31.4M 28.5M 32.5M 30.6M 27.8M 25.2M 20M 13.7M
Net debt (borrowings + leases - cash) (USD) — — — — — — — -35.6M 9.5M -29.6M
Cash flow detail
Operating cash flow (USD) -13M -17.8M 127M -99.3M -167M 299M -20.3M -184M -230M -184M
Purchases of property, plant and equipment (USD) 2.25M 801,000 1.88M -15.3M -5.03M -3.25M -4.12M -2.38M -1.26M -41,000
Change in receivables (cash effect) (USD) 218,000 20,000 -238,000 — — — — — — —
Change in payables (cash effect) (USD) 708,000 -41,000 -809,000 152,000 2.41M 1.92M -572,000 -377,000 -1.44M -524,000
Interest paid (cash effect) (USD) — — — — — — — — 0.00 -855,000
Income taxes paid (cash effect) (USD) — — — — — — — — 100,000 880,000
Share-based compensation (USD) 1.96M 5.35M 6.93M 16.3M 30.5M 40.8M 46.1M 42.8M 39.5M 26.7M
Operating cash flow before change in receivables (USD) -13.2M -17.8M 128M — — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -15.2M -18.6M 126M -115M -172M 295M -24.4M -187M -231M -184M
Income detail
Research and development expense (USD) 13.7M 29.9M 73M 101M 157M 189M 210M 192M 186M 123M
↳ 5y CAGR +69.2% +47.7% +21.3% +13.1% -4.7%
Total comprehensive income (USD) -15.1M -32.5M -52.3M -105M -190M -37.9M -137M -126M -119M -143M
Comprehensive income to owners (USD) -15.1M -32.5M -52.3M -105M -190M -37.9M -137M -126M -119M -143M
Reported Mar 24, 2020 Mar 26, 2019 Mar 24, 2020 Mar 24, 2020 Feb 25, 2021 Feb 24, 2022 Feb 28, 2023 Feb 26, 2025 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD), targeting first-in-human dosing in Australia no later than April 2027.

Continued progress across AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL062 (ABC-enabled alpha-synuclein siRNA for Parkinson's disease (PD) and Lewy body dementia (LBD)), each targeting first-in-human studies in Q2 2028.

Entered exclusive global license agreement with Genentech for AL050, Alector's brain-penetrant GCase enzyme replacement therapy (ERT), including a $100 million upfront payment and eligibility for up to $1.17 billion in milestone payments plus tiered royalties on net sales.

Completed underwritten offering for gross proceeds of approximately $75 million, priced at a premium to market, with participation from top-tier new and existing investors.

Alector Announces Pricing of Underwritten Offering Bull 0 Bear 5 Financing

PDF Version

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represents a premium of approximately 7.3% over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000.00 before deducting the underwriting discounts and commissions and other estimated offering expenses. All shares of common stock to be sold in the offering are being offered by Alector. The offering is expected to close on or about October 19, 2026, subject to the satisfaction of customary closing conditions.

The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, among others.

Alector anticipates using the net proceeds from the offering for general corporate purposes, which may include research, development and manufacturing of our product candidates, working capital, capital expenditures, other corporate expenses, and acquisitions of, or strategic transactions in, complementary products, technologies, or businesses.

Morgan Stanley & Co. LLC and BTIG, LLC are acting as joint lead book-running managers for the offering.

The securities described above are being offered by Alector pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department; or by email at [email protected]; or BTIG, LLC, 65 East 55th Street, New York, New York 10022, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Alector

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California.

Cautionary Note Regarding Forward-Looking Statements

This announcement contains forward-looking statements, including statements relating to Alector’s expectations regarding the anticipated use of proceeds, and the completion of the offering. These statements are subject to significant risks and uncertainties, and actual results could differ materially from those projected. Alector cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions, and the satisfaction of customary closing conditions related to the offering. There can be no assurance that Alector will be able to complete the offering. These and other risks are described more fully in Alector’s filings with the Securities and Exchange Commission (“SEC”), including Alector’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents Alector files with the SEC from time to time. Except to the extent required by law, Alector undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Alector Contacts: Argot Partners (investors) Laura Perry [email protected]

Argot Partners (media) David Rosen 646-461-6387 [email protected]

Primary Logo

Close

Are you sure you want to leave?

You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites.

Continue

Cancel

(e) Option Repricing On October 13, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Alector, Inc. (“Alector” or the “Company”) approved an option repricing. The repricing generally applied to stock options to purchase shares of the common stock of Alector that: (i) were granted to current employees under the Company’s 2019 Equity Incentive Plan, as amended (the “2019 Plan”), or the Company’s 2017 Stock Option and Grant Plan (together with the 2019 Plan, the “Plans”) and applicable award agreements thereunder; (ii) as of the effective date of the repricing, were held by continuing employees; and (iii) had an exercise price per share greater than $1.87 (the “Eligible Options”). The repriced options include Eligible Options held by each of Arnon Rosenthal, Ph.D., the Company’s Co-founder and Chief Executive Officer (options to purchase an aggregate of 2,421,197 shares with original exercise prices ranging from $6.48 to $23.70 per share) and Grace Wong-Sarad, the Company’s Chief Accounting Officer and principal accounting officer (options to purchase an aggregate of 87,385 shares with original exercise prices ranging from $9.46 to $23.70 per share).

Prompts

Alector, Inc. (ticker ALEC), listed in United States.

ETFs Holding Alector, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.05% 1,547 $ 3,109.47 Jun 30, 2026
DFSU 0.00% 3,867 $ 9,474.15 Nov 12, 2026
CORO 0.00% 1,565,502 $ 547.926K Nov 16, 2026